Used in cancer research and therapy development, particularly targeting tumors that overexpress the EphA2 receptor, such as lung, prostate, and ovarian cancers. It functions by binding specifically to EphA2, which helps inhibit tumor cell growth and survival. This antibody has been explored in clinical trials to evaluate its efficacy in blocking signaling pathways involved in cancer progression and angiogenesis. It also serves as a reference standard in developing biosimilars and immunoassays for EphA2 detection.